PriceTargets.com logo

Opthea - OPT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $1.33
  • Forecasted Upside: -60.90%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
$3.41 As of 04/25/2025 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for OPT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Opthea Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OPT

Analyst Price Target is $1.33
▼ -60.90% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Opthea in the last 3 months. The average price target is $1.33, with a high forecast of $2.00 and a low forecast of $1.00. The average price target represents a -60.90% upside from the last price of $3.41.

This chart shows the closing price for OPT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 6 polled investment analysts is to hold stock in Opthea. This rating has held steady since February 2025, when it changed from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
3/29/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
4/28/2025

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/25/2025HC WainwrightDowngradeBuy ➝ Neutral$12.00 ➝ $2.00
3/25/2025Leerink PartnersDowngradeOutperform ➝ Market Perform$12.00 ➝ $1.00
3/25/2025Jefferies Financial GroupReiterated RatingBuy ➝ Underperform$8.00 ➝ $1.00
3/24/2025Leerink PartnrsDowngradeStrong-Buy ➝ Hold
3/24/2025OppenheimerDowngradeOutperform ➝ Market Perform
2/28/2025HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
1/29/2025HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
12/17/2024Canaccord Genuity GroupUpgradeStrong-Buy
9/3/2024HC WainwrightLower TargetBuy ➝ Buy$14.00 ➝ $12.00
9/18/2023CitigroupLower Target$22.00 ➝ $12.00
9/13/2023OppenheimerLower TargetOutperform ➝ Outperform$31.00 ➝ $16.00
8/1/2023HC WainwrightReiterated RatingBuy ➝ Buy$14.00
4/17/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$23.00
3/13/2023OppenheimerLower TargetOutperform$36.00 ➝ $31.00
3/9/2023CitigroupLower Target$24.00 ➝ $22.00
2/24/2023HC WainwrightReiterated RatingBuy$14.00
12/8/2022HC WainwrightInitiated CoverageBuy$14.00
9/16/2022CitigroupLower TargetBuy$45.00 ➝ $44.00
4/26/2022Leerink PartnersInitiated CoverageOutperform$25.00
4/13/2022Truist FinancialLower Target$25.00 ➝ $13.00
11/18/2020CIBCReiterated RatingHold$26.00
11/17/2020Smith Barney CitigroupInitiated CoverageBuy$48.00
11/11/2020Leerink PartnersInitiated CoverageOutperform$33.00
11/11/2020OppenheimerInitiated CoverageOutperform$36.00
11/11/2020Truist FinancialInitiated CoverageBuy$25.00
(Data available from 4/28/2020 forward)

News Sentiment Rating

0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
11/29/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
12/29/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2025
  • 6 very positive mentions
  • 11 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
2/27/2025
  • 5 very positive mentions
  • 17 positive mentions
  • 15 negative mentions
  • 7 very negative mentions
Mentions as of
3/29/2025
  • 1 very positive mentions
  • 8 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
4/28/2025

Current Sentiment

  • 1 very positive mentions
  • 8 positive mentions
  • 6 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Opthea logo
Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Read More

Today's Range

Now: $3.41
Low: $3.41
High: $3.41

50 Day Range

MA: $3.66
Low: $3.07
High: $5.11

52 Week Range

Now: $3.41
Low: $1.79
High: $6.30

Volume

N/A

Average Volume

27,565 shs

Market Capitalization

$524.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Opthea?

The following equities research analysts have issued research reports on Opthea in the last twelve months: Canaccord Genuity Group Inc., HC Wainwright, Jefferies Financial Group Inc., Leerink Partners, Leerink Partnrs, and Oppenheimer Holdings Inc..
View the latest analyst ratings for OPT.

What is the current price target for Opthea?

0 Wall Street analysts have set twelve-month price targets for Opthea in the last year. Their average twelve-month price target is $1.33, suggesting a possible downside of 60.9%. HC Wainwright has the highest price target set, predicting OPT will reach $2.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $1.00 for Opthea in the next year.
View the latest price targets for OPT.

What is the current consensus analyst rating for Opthea?

Opthea currently has 1 sell rating, 4 hold ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OPT, but not buy more shares or sell existing shares.
View the latest ratings for OPT.

What other companies compete with Opthea?

Other companies that are similar to Opthea include Vericel, Twist Bioscience, Metsera, Schrödinger and Denali Therapeutics. Learn More about companies similar to Opthea.

How do I contact Opthea's investor relations team?

Opthea's physical mailing address is LEVEL 4 650 CHAPEL STREET, SOUTH YARRA VICTORIA C3, 3141. The company's listed phone number is 61-3-9826-0399 and its investor relations email address is [email protected]. The official website for Opthea is www.opthea.com. Learn More about contacing Opthea investor relations.